Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 24, 2017. The report details the announcement of 96-week data from the LATTE-2 Phase IIb study conducted by ViiV Healthcare, a global specialist HIV company majority-owned by GSK. The study evaluates long-acting injectable formulations of cabotegravir and rilpivirine as a two-drug regimen for HIV-1 treatment.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial results and does not contain financial statements or operational financial data.
Material Changes and Clinical Results
The primary material update is the publication of 96-week maintenance treatment results from the LATTE-2 study, demonstrating the durability of a long-acting injectable HIV regimen compared to daily oral therapy.
- Viral Suppression Rates: At 96 weeks, the two-drug injectable regimen dosed every eight weeks achieved a 94% suppression rate, and the four-week dosing group achieved 87%. These rates were comparable to the 84% rate observed in the three-drug oral regimen group.
- Virologic Failure: Two patients in the eight-week dosing group and one patient in the oral regimen group met failure criteria. No patients in the four-week dosing group experienced virologic failure. No evidence of resistance was found at failure.
- Safety Profile: Injection site pain was the most common reaction, with 84% mild and 15% moderate severity, lasting a median of three days. Serious adverse events occurred in 6% of injectable patients and 5% of oral patients; none were drug-related.
Guidance, Outlook, and Risks
Management Commentary: John C. Pottage Jr., Chief Scientific and Medical Officer for ViiV Healthcare, stated that the results confirm the durability and tolerability of the long-acting regimen. He noted that parenteral administration removes the daily dosing burden and highlighted the zero virologic failures in the four-week group.
Outlook: Management anticipates results from the Phase III program with long-acting cabotegravir and rilpivirine in 2018.
Risks and Contingencies: The filing includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ due to risks described in the 2016 Annual Report on Form 20-F. Specific clinical risks mentioned include severe skin rashes, allergic reactions, depression, liver problems, and immune reconstitution syndrome associated with the investigational drugs.
Investor Verification Checklist
- Verify the timeline and enrollment criteria for the upcoming Phase III program expected to report in 2018.
- Review the full safety data regarding injection site reactions and long-term tolerability in the Phase III trials.
- Assess the competitive landscape for long-acting HIV treatments and potential market share implications.
- Confirm the regulatory pathway and approval status for cabotegravir and rilpivirine in key markets.
- Monitor ViiV Healthcare's financial performance and its impact on GSK's overall portfolio, as this filing contains no direct financial metrics.